RxDoctor Payments Data

Florian Gegaj, MD

Internal Medicine · The Villages, FLNPI 1205099660

Payments from drug & device makers

$912in general payments, 2019–2025

Across 37 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$169
  • Edwards Lifesciences$154
  • Novo Nordisk$92
  • Johnson & Johnson$72
  • Novartis$71
  • Amarin Pharma, Inc.$71
  • plus $283 from 12 others

What the payments were for

  • Food & beverage$72880%
  • Education$152%
  • Gifts$16919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$2,190,216
Medicare patients
1,969
Services billed
36,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$294,350
OzempicSemaglutide93$169,093
JanuviaSitagliptin Phosphate75$128,591
XareltoRivaroxaban51$81,649
JardianceEmpagliflozin23$38,643
MounjaroTirzepatide33$34,275
TrulicityDulaglutide13$32,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$30,471
TradjentaLinagliptin12$16,787
Atorvastatin Calcium1,597$15,559
EntrestoSacubitril/Valsartan12$14,485
Levothyroxine Sodium1,094$12,219
Rosuvastatin Calcium673$9,777
SynthroidLevothyroxine Sodium195$9,177
Omeprazole593$8,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$28$301,681222 claims
Novo NordiskOzempic$92$169,09393 claims
Johnson & JohnsonXarelto$72$81,64951 claims
Lilly USA, LLCMounjaro, Trulicity$19$66,36646 claims
Boehringer IngelheimJardiance, Tradjenta$15$55,43035 claims
GSKTrelegy Ellipta$46$30,47123 claims
NovartisEntresto$71$14,48512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →